Ironwood Pharmaceuticals (IRWD) Revenue (2010 - 2026)

Ironwood Pharmaceuticals has disclosed Revenue across 17 years of filings, most recently posting $106.5 million for Q1 2026.

• Revenue for Q1 2026 came in at $106.5 million, up 158.87% year-over-year; the trailing twelve-month figure through Mar 2026 was $361.5 million (up 13.8% YoY), and the FY2025 annual result was $296.2 million, down 15.72% from the prior year.
• Revenue came in at $106.5 million for Q1 2026 at Ironwood Pharmaceuticals, up from $47.7 million in the prior quarter.
• In the past five years, Revenue ranged from a high of $122.1 million in Q3 2025 to a low of $41.1 million in Q1 2025.
• The 5-year median for Revenue is $97.5 million (2022), against an average of $94.6 million.
• Across the five-year window, Revenue sank 47.31% in 2025 and jumped 158.87% in 2026, its largest moves.
• Ironwood Pharmaceuticals' Revenue stood at $107.2 million in 2022, then increased by 9.66% to $117.6 million in 2023, then decreased by 22.98% to $90.5 million in 2024, then tumbled by 47.31% to $47.7 million in 2025, then soared by 123.24% to $106.5 million in 2026.
• The last three Revenue figures came in at $106.5 million (Q1 2026), $47.7 million (Q4 2025), and $122.1 million (Q3 2025), per Business Quant data.